Biogen has a partnership in place with Verily, Google’s life sciences arm – in which they will use sensors and data analytics to understand how multiple sclerosis presents itself differently from patient to patient. Through Biogen’s discussions and data sharing with Google, Koppel came to the following conclusions:
The Silicon Valley giant recognizes that “current payers, using actuarial math – it’s like the 19th century,” he said. Google’s found it can pool big data, and figure out real-life outcomes in actual people.
Read Full Article »